biostudies-literatureUnknown11(6)Chen GFHumanity and Health Medical GroupCheng Si-Yuan (China-International) Hepatitis Research Foundation<h4>Background</h4>Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions.<h4>Methods</h4>A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate thPloS onee0155934https://www.ebi.ac.uk/biostudies/studies/S-EPMC4898683biostudies-literatureWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.PMC4898683Jia JDWang GQZhang YXWang CLiu JLShang JHan YJia ZSWang XJZhang WHRen HYang XXWong AZhuang HHou JLLi BShao QWu VWei LCheng JDuan ZPJi DWang JPChen JLi FWang YDChen GFXie QNiu XXFu QCLu LGFan JGLau GDou XGDu NfalseWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.<h4>Background</h4>Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions.<h4>Methods</h4>A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate th2016-01-01T00:00:00Z20162025-05-29T19:42:36.538Z2019-03-26T22:51:58ZS-EPMC48986832727608110.1371/journal.pone.0155934